It has been confirmed that the inhibition activity of GSK-3β exerts protective effects on the brain, heart, and kidney in both healthy and diabetic conditions [6, 12, 17] while amounts of reports showed that GSK-3β is activated in diabetes due to the impairment of its upstream pathways, thus affecting the protective effect of postconditioning methods as well as pharmacological agents [11–13]. Here, GSK3B is linked to diabetes mellitus.